The Australian government has suspended trials of the controversial oral abortifacient mifepristone, formerly known as RU-486, which was originally developed by Hoechst Roussel. The suspension appears to be a result of fears that the women taking part may not have been properly informed of possible side effects with the drug. Side effects may include vaginal bleeding, nausea, vomiting, rashes, malaise and uterine pain caused by the required co-administration of a gemeprost pessary.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze